



# PHARMX TECHNOLOGIES LIMITED

ABN 25 000 091 305  
AND ITS CONTROLLED ENTITIES

## Appendix 4D

---

Name of entity

Pharmx Technologies Limited

ABN or equivalent company reference

25 000 091 305

Half year ended ('current period')

31 December 2024

Financial year ended  
(‘previous corresponding period for  
Balance Sheet’)

30 June 2024

Half year ended  
(‘previous corresponding period for  
Statement of Comprehensive Income and  
Cash Flow Statement’)

31 December 2023



## PHARMX TECHNOLOGIES LIMITED

ABN 25 000 091 305  
AND ITS CONTROLLED ENTITIES

### Results for announcement to the market

---

Extracts from this report for announcement to the market

1. Revenue from ordinary activities	Up 17.0% to	\$3,773,000
2. Profit from ordinary activities after tax attributable to members	N/A	\$155,000
3. Profit for the period attributable to members	N/A	\$155,000

Statement regarding dividends and distributions	No dividends have been paid or declared during the period or previous financial period.
Record date for determining entitlements	N/A

	Current Period 31 December 2024	Previous Corresponding Period 30 June 2024
Net tangible assets/(liabilities) per security (excluding intangible assets and assets held for sale, net)	0.71 cents	0.51 cents



HALF YEARLY  
REPORT  
FOR THE 6 MONTHS  
ENDED  
31 DECEMBER 2024

## Contents

	<i>Page</i>
Directors' Report	2
Auditor's Independence Declaration	6
Consolidated Statement of Profit or Loss and Other Comprehensive Income	7
Consolidated Statement of Financial Position	8
Consolidated Statement of Changes in Equity	9
Consolidated Statement of Cash Flows	10
Notes to the Consolidated Financial Statements	11
Directors' Declaration	20
Independent Auditor's Review Report	21



## Directors' Report

The Directors present their report, together with the financial statements, on the Consolidated Entity consisting of Pharmx Technologies Limited ('Group', or the 'Company') and the entities it controlled for the half-year ended 31 December 2024.

### Directors

The following were directors of Pharmx Technologies Limited since the beginning of the half-year and up to the date of this report, unless a different period is stated below:

Nick England	Chairman
Jon Newbery	Executive Director (assumed the role of Interim CFO effective 1 <sup>st</sup> February 2024)
Jayne Shaw	Non-executive Director
Dennis Bastas	Non-executive Director
Sandy Mellis	Alternate director for Dennis Bastas (effective 6 <sup>th</sup> September 2024)

### Company Secretary

Chris Fernandes

### Principal Activities

Pharmx Technologies Limited (ASX: PHX) is a technology and software development business. The key business activities relate to Pharmx, an electronic ordering and invoicing gateway, Pharmxchange, an online sales and marketing platform, integrated with Pharmx and the provision of data and analytics services to the pharmacy industry.

The disposal of the pharmacy software business (developed and distributed pharmacy point-of-sale, dispensing and multi-site retail management software) was completed in the prior financial year, with the deferred consideration received in October 2024.

### Operating Results

Revenue from operations for the half-year was \$3,773,000, up 17% on the prior period (half-year ended 31 December 2023: \$3,235,000).

The profit before tax from operations was \$379,000 (half-year ended 31 December 2023: profit of \$406,000, which included \$66,000 of non-recurring legal costs relating to the now settled dispute between Fred IT Group Pty Ltd ('Fred IT') and Pharmx Pty Ltd ('Pharmx')).

As indicated previously, significant investments were made in the half which has led to a decline in underlying operating profit. Increased investment has been made in resources, specifically development resources, marketing capability and IT infrastructure to reposition and rebrand the business, enhance the platforms and put in place the infrastructure for new capabilities, particularly in data analytics. As a result, personnel costs, before capitalisation have increased by 45% to \$2,097,000 (31 December 2023: \$1,444,000), marketing costs have increased by 155% to \$166,000 (31 December 2023: \$65,000) and Technology and communication and cloud costs are up 28% to \$258,000 (31 December 2023: \$201,000).

Amortisation of the continued investment into both Gateway and Marketplace means the cost of amortisation of software development has increased in the current half-year compared to the prior period.

## Directors' Report continued

### Operating Results continued

During the half-year the Group agreed to an early termination of the revenue share agreement with Alchemy relating to the acquisition of the Pharmxchange intellectual property. This resulted in a reduction in the amount payable under the agreement of \$824,000. As this amount related to the original maximum amount payable for the intellectual property this amount was netted against intangible assets, where the original asset was recognised.

The net profit after income tax for the half-year ended 31 December 2024 was \$155,000 (half-year ended 31 December 2023: loss of \$1,732,000).

### Dividends

There were no dividends paid, recommended or declared during the current half-year, previous financial year or subsequent to the end of the current half-year.

### Review of Operations

In line with our growth strategy for FY25, the business has increased its supplier partners by 10% year to date, as well as increasing the total number of accounts 4%. This has resulted in an uplift in volumes across our platforms highlighted by the following metrics:

#### *Gateway:*

- Invoice value in H1 FY25 was up 18% year on year and up 15% on H2 FY24
- 55% year on year increase in revenue from New Zealand suppliers
- 35% increase in Network User revenue

#### *Marketplace:*

- 235% increase in the number of orders placed through our marketplace in H1 FY25 compared with H1 FY24, and an 82% increase on H2 FY24
- The value of invoices processed in H1 FY25 was up 1,070% compared to H1 FY24 and 169% from H2 FY24
- Average Order Value (AOV) in H1 FY25 was 154% higher than H1 FY24 and 37% higher than H2 FY24

Pharmx recently announced a new and significant strategic partnership with Toniq, the dominant provider of pharmacy POS and dispense software solutions in New Zealand which will transform our business in that country. A member of the global healthcare technology group Clanwilliam, Toniq supports over 900 pharmacies and holds an estimated 85% market share in New Zealand's pharmacy POS and dispense software sector.

Under the terms of the partnership, pharmacies within the Toniq POS network can migrate to the Pharmx Gateway enabling real-time inventory ordering, automated e-invoice generation and seamless supplier connectivity. This partnership also offers Pharmx's suppliers a broader reach and more opportunities to scale business growth across the ANZ region.

Other notable new partners joining the platforms in H1 FY25 include:

- Pave Brands, a sales broker acting on behalf of Kind Regards the distributing partner of Australian iconic FMCG brand THANK YOU
- Perdays, a new premium vendor management system (VMS) supplier specialising in prenatal wellbeing
- Healthylife, the pharmacy distributor owned by Woolworths
- Canary IT, a Microsoft platinum partner and new point-of-sale (POS) Vendor which completes the PharmX integration with Microsoft LS retail and business central

## Directors' Report continued

### Review of Operations continued

During the half year Pharmx completed a rebranding initiative to transform our brand and positioning to align with our growth objectives and reinforce our leadership in the pharma-tech sector. This evolution is driven by a deep understanding of the challenges pharmacists face - navigating stock and ordering complexities while striving to provide reassuring care to the community. By repositioning Pharmx, we are not only addressing a critical industry pain point but also strengthening our relationships with pharmacy networks, suppliers, and cross-industry partners. Our brand promise *"You're in safe hands with the biggest pharmacy ordering network,"* reflects our commitment to reliability, efficiency, and trust. This strategic shift will amplify our influence, enhance stakeholder value, and position Pharmx for sustained growth in an evolving healthcare landscape.

The early termination of the revenue share agreement with Alchemy relating to the acquisition of the Pharmxchange intellectual property also enables Pharmx to invest in the next phase of the Marketplace growth, as part of a broader investment program, to offer more value to our customers and enable stronger and more efficient scale. This program will result in the delivery of a Single Platform; fully integrated into the EDI and Data & Analytics solutions and operating under a single brand proposition to maximise revenue and efficiency.

During the half there has been a gradual increase in operating costs which has resulted in an uplift in revenues. This investment supports the growth agenda focussed on increased suppliers and account activity, developing the analytics capability and to increase future security, scalability and efficiency of the Pharmx Gateway platform.

### Outlook

Looking forward, the FY25 strategy remains unchanged: increasing the number of suppliers across the Pharmx network; driving engagement with pharmacies; increasing transaction volumes; and enhancing both our analytics capabilities and addressable market.

The Board has recently approved investment to accelerate the development of key initiatives, beginning with the Pharmx Supplier Portal. This marks the first step toward enhancing ordering services, vertical EDI integration, and expanding full-service analytics, each reinforcing Pharmx's position as ANZ's leading pharmacy ordering network. This investment represents a significant milestone in Pharmx's transformation and seeks to unlock further growth opportunities, strengthen industry relationships, and advance our mission to improve healthcare by reimagining industry connections.

The new Supplier Portal reduces barriers to market entry, creating efficiencies for both suppliers and Pharmx, while streamlining product availability and simplifying ordering for pharmacies. Slashing supplier onboarding times from 12 weeks to one day, through the "Trade in A Day" initiative enables near-instant access to a network of ~6,000 pharmacies (99% of the ANZ market) which will be a game-changer for suppliers seeking broader distribution. For pharmacies, the portal's expanded supplier base will increase SKU variety and availability, strengthening Pharmx's 80,000+ product catalogue and further simplifying the procurement process. This launch will also mark the first product offering under Pharmx's rebranded identity, reinforcing our strategy.

Moving forward there will be ongoing enhancement of existing solutions as well as the delivery of new services. Through improved services, systems and technologies the Group will continue to meet the needs of pharmacies, suppliers and point-of-sale software vendors.

## Directors' Report continued

### Financial Position

At 31 December 2024 the Consolidated Entity had net assets of \$16,151,000 (30 June 2024: \$15,972,000). Working capital, current assets less current liabilities, is a surplus of \$4,609,000 (30 June 2024: \$4,419,000).

The cash position was \$4,482,000 (30 June 2024: \$13,136,000), a decrease of \$8,654,000. During the period the Group paid Fred IT Pty Ltd \$9,898,000, which included the original judgement sum of \$8,128,000 and an additional \$1,770,000 relating to costs and interest in accordance with the final Orders issued by the Victorian Supreme Court on 8 August 2024 relating to the appeal filed by Fred IT in relation to the original decision in the PharmX court case.

Operating cashflows for the period, excluding the payment to Fred IT and the net tax refund, were \$128,000 (31 December 2023, excluding funds outflow relating to the pharmacy software business prior to sale of \$214,000 and one-off legal costs of \$66,000: \$553,000). As in previous years, the overall cash position benefited from a tax refund (including research and development incentive) of \$862,000 that was received in the period (\$1,663,000 in the half-year ended 31 December 2023, which included the pharmacy software business).

These inflows, together with the deferred consideration of \$1,255,000 received in the half from the sale of the pharmacy software business, have been used to fund the ongoing investment in new product development during the period of \$924,000 (\$1,080,000 in the half-year ended 31 December 2023) of which \$655,000 is capitalised research and development.

### Going Concern

The Directors have prepared these financial statements on the basis that the Company is a going concern.

### Events Subsequent to Reporting Date

No matters or circumstances have arisen since 31 December 2024 that have significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

### Auditor's Independence Declaration

The auditor's independence declaration as required by section 307C of the Corporations Act 2001 is set out on page 6.

### Rounding of Amounts

The Company is an entity to which ASIC legislative instrument 2016/191 applies and, accordingly, amounts in the financial statements have been rounded to the nearest thousand dollars unless otherwise stated.

This Report of the Directors is signed in Sydney in accordance with a resolution of the Board of Directors.



**Nick England**  
Chairman



**Jon Newbery**  
Director

Dated: 19 February 2025



DECLARATION OF INDEPENDENCE BY VIJYATA KIRPALANI TO THE DIRECTORS OF PHARMX TECHNOLOGIES LIMITED

As lead auditor for the review of PharmX Technologies Limited for the half-year ended 31 December 2024, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of PharmX Technologies Limited and the entities it controlled during the period.



Vijyata Kirpalani  
Director

BDO Audit Pty Ltd

Sydney, 19 February 2025

Consolidated Statement of Profit or Loss and Other Comprehensive Income  
for the half-year ended 31 December 2024

	Note	31 December 2024 \$'000	31 December 2023 \$'000
<b>Revenue from continuing operations</b>	2	<b>3,773</b>	<b>3,235</b>
<b>Expenses related to continuing operations</b>			
Cost of sales		(669)	(610)
Marketing		(166)	(65)
Employee benefits	3	(1,443)	(1,022)
Share-based payments		(24)	(39)
Technology, communication and cloud costs		(258)	(201)
Legal		(25)	(70)
Professional fees, consulting and other		(247)	(270)
Depreciation and amortisation	3	(641)	(578)
Finance costs		(23)	(30)
Research and development tax benefit		102	56
<b>Profit from continuing operations before income tax</b>		<b>379</b>	<b>406</b>
Income tax expense	4	(224)	(170)
<b>Profit from continuing operations</b>		<b>155</b>	<b>236</b>
Profit / (loss) from discontinued operations, including loss on disposal	5	-	(1,968)
<b>Profit / (loss) from continuing operations</b>		<b>155</b>	<b>(1,732)</b>
Other comprehensive income for the half-year, net of tax		-	-
<b>Total comprehensive income for the half-year attributable to the owners of Pharmx Technologies Limited</b>		<b>155</b>	<b>(1,732)</b>
<b>Earnings per share</b>	6	<b>Cents</b>	<b>Cents</b>
<b>Basic earnings per share</b>		<b>0.03</b>	<b>(0.29)</b>
<b>Diluted earnings per share</b>		<b>0.03</b>	<b>(0.29)</b>

The consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

## Consolidated Statement of Financial Position as at 31 December 2024

	Note	31 December 2024 \$'000	30 June 2024 \$'000
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		4,482	13,136
Trade and other receivables	8	912	2,271
Income tax receivable		35	883
Other assets		239	79
		<b>5,668</b>	<b>16,369</b>
<b>Non-current assets</b>			
Property, plant and equipment		30	17
Right of use assets		172	226
Intangibles	9	11,894	12,930
Deferred tax assets		115	223
Security deposits		90	92
		<b>12,301</b>	<b>13,488</b>
<b>Total Assets</b>		<b>17,969</b>	<b>29,857</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables		809	11,686
Provisions		79	150
Lease liability		113	107
Unearned income		58	7
		<b>1,059</b>	<b>11,950</b>
<b>Non-current liabilities</b>			
Other payables		-	883
Provisions		69	47
Lease liability		75	133
Deferred tax liability		615	872
		<b>759</b>	<b>1,935</b>
<b>Total liabilities</b>		<b>1,818</b>	<b>13,885</b>
<b>Net assets</b>		<b>16,151</b>	<b>15,972</b>
<b>Equity</b>			
Issued capital	10	93,970	93,970
Reserves		48	24
Accumulated losses		(77,867)	(78,022)
<b>Total Equity</b>		<b>16,151</b>	<b>15,972</b>

The consolidated statement of financial position should be read in conjunction with the accompanying notes.

Consolidated Statement of Changes in Equity for the half-year ended  
31 December 2024

	Issued capital	Share- based Payments Reserve	Accumulated losses	Total equity
Note	\$'000	\$'000	\$'000	\$'000
<b>Balance at 1 July 2024</b>	<b>93,970</b>	<b>24</b>	<b>(78,022)</b>	<b>15,972</b>
Profit after income tax	-	-	155	155
Performance rights issued and current year expense	-	24	-	24
<b>Balance at 31 December 2024</b>	<b>93,970</b>	<b>48</b>	<b>(77,867)</b>	<b>16,151</b>
<b>Balance at 1 July 2023</b>	<b>98,405</b>	<b>59</b>	<b>(76,253)</b>	<b>22,211</b>
Loss after income tax	-	-	(1,732)	(1,732)
Capital return	(4,489)	-	-	(4,489)
Performance rights exercised	54	(54)	-	-
Performance rights issued and current year expense	-	39	-	39
<b>Balance at 31 December 2023</b>	<b>93,970</b>	<b>44</b>	<b>(77,985)</b>	<b>16,029</b>

The consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Consolidated Statement of Cash Flows for the half-year ended  
31 December 2024

	31 December 2024 \$'000	31 December 2023 \$'000
<b>Cash flows from operating activities</b>		
Receipts from customers	4,192	4,683
Payments to suppliers and employees	(14,079)	(4,503)
Interest and other revenue received	117	93
Research and development incentive received, net of income tax paid	862	1,663
<b>Net cash from operating activities</b>	<b>(8,908)</b>	<b>1,936</b>
<b>Cash flows from investing activities</b>		
Payments for property, plant and equipment	(18)	(16)
Payments for intangible assets	(924)	(1,080)
Disposal of discontinued operations, net of cash disposed and transaction costs	1,255	3,358
<b>Net cash generated in investing activities</b>	<b>313</b>	<b>2,262</b>
<b>Cash flows from financing activities</b>		
Principal paid on lease liabilities	(52)	(67)
Interest paid on lease liabilities	(7)	(8)
Capital return paid	-	(4,489)
<b>Net cash used in financing activities</b>	<b>(59)</b>	<b>(4,564)</b>
<b>Net decrease in cash and cash equivalents</b>	<b>(8,654)</b>	<b>(366)</b>
Cash and cash equivalents at beginning of the period	13,136	12,806
<b>Cash and cash equivalents at end of the period</b>	<b>4,482</b>	<b>12,440</b>

The consolidated statement of cash flows should be read in conjunction with the accompanying notes.



## Notes to the Consolidated Financial Statements for the half-year ended 31 December 2024

This general purpose financial report includes the consolidated financial statements and notes of Pharmx Technologies Limited and controlled entities ('Consolidated Entity', or 'Group', or the 'Company'). Pharmx Technologies Limited is a listed public company, incorporated and domiciled in Australia.

The presentational and functional currency is Australian dollars.

### Note 1: Basis of preparation

#### a) Basis of preparation

The half-year consolidated financial statements have been prepared in accordance with the requirements of the Corporations Act 2001, Australian Accounting Standard AASB 134: Interim Financial Reporting, Australian Accounting Interpretations and other authoritative pronouncements of the Australian Accounting Standards Board.

These half-year financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2024 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The half-year consolidated financial statements have been prepared using the same accounting policies consistently applied by the entities in the Consolidated Entity as used in the annual financial statements for the year ended 30 June 2024.

#### b) Reporting basis and conventions

The financial statements have been prepared on an accruals basis and are based on historical costs; modified where applicable by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

#### c) Going concern basis

The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of business.

#### d) New, revised or amending Accounting Standards and Interpretations adopted

The Consolidated Entity has adopted all the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

There were no standards and amendments that applied for the first time that had an impact on the consolidated financial statements of the Consolidated Entity for the half-year reporting period commencing 1 July 2024.

Any new, revised or amending Accounting Standards or Interpretations that are not yet effective have not been adopted.

Notes to the Consolidated Financial Statements for the half-year ended  
31 December 2024

	31 December 2024 \$'000	31 December 2023 \$'000
<b>Note 2: Revenue and other income</b>		
<i>Revenue from contracts with customers from continuing operations</i>		
Rendering of services	3,656	3,142
	<b>3,656</b>	<b>3,142</b>
<i>Other income</i>		
Interest received	117	93
	<b>117</b>	<b>93</b>
<b>Total revenue from continuing operations</b>	<b>3,773</b>	<b>3,235</b>

**Note 3: Expenses**

<i>Employee benefits</i>		
Employee benefits expenses	2,097	1,444
Capitalised development costs	(654)	(422)
<b>Total employee benefits related to continuing operations</b>	<b>1,443</b>	<b>1,022</b>
<i>Depreciation and amortisation</i>		
Software development	582	532
Leased assets	54	41
Property, plant and equipment	5	5
<b>Total depreciation and amortisation related to continuing operations</b>	<b>641</b>	<b>578</b>

Notes to the Consolidated Financial Statements for the half-year ended  
31 December 2024

	31 December 2024 \$'000	31 December 2023 \$'000
<b>Note 4: Income tax</b>		
<i>Current income tax:</i>		
Current period income tax charge	352	111
Adjustment for current income tax of items credited directly to equity (amortisation of capital raising costs)	10	17
Adjustment for current income tax of previous year	20	(4)
Less income tax estimate related to discontinued operations	-	(17)
<i>Deferred tax:</i>		
Utilisation and reversal of temporary differences	(158)	269
Less Utilisation and reversal of temporary differences related to sale of business	-	(206)
<b>Total income tax</b>	<b>224</b>	<b>170</b>

In the financial year ended 30 June 2023 the Company claimed an accelerated tax benefit for the cost of acquiring the intellectual property relating to the Pharmxchange platform. Following the early settlement of the remaining liability with Alchemy Healthcare Pty Ltd (Alchemy), see note 9 for further details, the excess accelerated tax benefit has been reversed in the current income tax year. This has impacted the current period income tax charge and the utilisation and reversal of temporary differences but has minimal impact on the net tax expense for the period.

The potential future tax benefits arising from tax losses and temporary differences have been recognised as deferred tax assets only to the extent that:

- the Group is likely to derive future assessable income of a nature and amount sufficient to enable the benefits to be realised;
- no changes or proposed changes in legislation are likely to adversely affect the Group's ability to realise these benefits; and
- the Group is likely to continue to comply with the conditions for deductibility of losses imposed by tax legislation.

## Note 5: Discontinued operations and disposal of business

On 20 July 2023, the Group signed a Share Sale and Purchase Agreement for the sale of the pharmacy software business to Jonas Software AUS Pty Ltd. The pharmacy software business comprised 2 legal entities, Corum Health Pty Ltd and Amfac Pty Ltd, which develop and distribute business software for the pharmacy industry, including point-of-sale and pharmaceutical dispensing software and multi-site retail management and provides support services and computer hardware.

The consideration for the sale was cash of \$6,250,000, subject to customary completion adjustments. The sale included the intellectual property rights to run the business, the rights of the pharmacy software business under the existing contracts, goodwill, operational staff to run the business and business records.

Completion of the sale occurred 30 September 2023, and consideration of \$4,750,000 was received at completion, with further deferred consideration of \$1,255,000, after customary completion adjustments, was received in October 2024.

The final loss on disposal before transaction costs reported in the year ended 30 June 2024 was \$419,000 with the total loss relating to the discontinued operations after income tax being \$1,864,000.

Notes to the Consolidated Financial Statements for the half-year ended  
31 December 2024

	31 December 2024 \$'000	31 December 2023 \$'000
<b>Note 6: Earnings per share ('EPS')</b>		
<i>Reconciliation of earnings:</i>		
Profit after income tax from continuing operations attributable to owners of the Company	155	236
Loss after income tax from discontinued operations attributable to owners of the Company	-	(1,968)
<b>Profit / (loss) after income tax attributable to owners of the Company</b>	<b>155</b>	<b>(1,732)</b>
	<b>Number</b>	<b>Number</b>
Weighted average number of ordinary shares used in calculating basic earnings per share	598,506,789	597,852,577
Weighted average number of ordinary shares used in calculating diluted earnings per share <sup>(i)</sup>	615,752,713	609,800,267

(i) Potential ordinary shares are only treated as dilutive when they would decrease earnings per share.

## Note 7: Operating segments

### *Identification of reportable operating segments*

The Group is organised into one operating segment: Health Services. During the previous financial year, the pharmacy software portion of Health Services was classified as held for sale. Refer to note 5 for further details.

This operating segment is based on internal reports reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. Consideration is given to the nature and distinctiveness of the products or services sold, the manner in which they are provided and the organisational structure.

The CODM review profit / (loss) before income tax ('segment result'). The accounting policies adopted for reporting to the CODM are consistent with those adopted in the financial statements.

The Group operates predominantly in Australia and New Zealand.

### *Types of services*

The principal services of each operating segment are as follows:

- Health Services continuing operations – which develops and provides access to business software for the pharmacy industry with emphasis on providing Gateway, Marketplace and Data & Analytics services to the pharmacy industry.
- Health Services discontinued operations – which developed and distributed business software for the pharmacy industry with emphasis on point-of-sale and pharmaceutical dispensing software, multi-site retail management and providing support services and computer hardware to pharmacy customers. The sale of this segment completed in the previous financial year, refer to note 5 for further details.

## Notes to the Consolidated Financial Statements for the half-year ended 31 December 2024

### Note 7: Operating segments continued

#### *Intersegment transactions*

An internally determined transfer price is set for all inter-segment sales. This price is reset annually and is based on arm's length pricing. All such transactions are eliminated on consolidation.

Corporate charges are allocated to reporting segments based on the segments' overall proportion of revenue generation within the Group or estimates of the time individuals apply to each segment, which is representative of likely consumption of head office expenditure.

For the purpose of segment reporting and understanding segment performance, the net benefit of research and development tax incentives are disclosed in the segment to which they relate.

Following the sale of the pharmacy software business in the previous financial year there are no intersegment transactions to be eliminated in the current financial year.



Notes to the Consolidated Financial Statements for the half-year ended  
31 December 2024

Note 7: Operating segments continued

<i>Segment performance</i>	Health Services continuing operations \$'000	Health Services discontinued operations \$'000	Intersegment eliminations /unallocated \$'000	Consolidated \$'000
<b>Half-year to 31 December 2024</b>				
<b>Revenue</b>				
Rendering of services	3,656	-	-	3,656
Interest and other revenue	117	-	-	117
<b>Total revenue</b>	<b>3,773</b>	<b>-</b>	<b>-</b>	<b>3,773</b>
<b>Profit before income tax expense</b>	<b>379</b>	<b>-</b>	<b>-</b>	<b>379</b>
Income tax expense	(224)	-	-	(224)
<b>Profit after income tax expense</b>	<b>155</b>	<b>-</b>	<b>-</b>	<b>155</b>
Depreciation and amortisation of segment assets	641	-	-	641
<b>As at 31 December 2024</b>				
Total Assets	17,969	-	-	17,969
Total Liabilities	(1,818)	-	-	(1,818)

Notes to the Consolidated Financial Statements for the half-year ended  
31 December 2024

Note 7: Operating segments continued

<i>Segment performance</i>	Health Services continuing operations \$'000	Health Services discontinued operations \$'000	Intersegment eliminations /unallocated \$'000	Consolidated \$'000
<b>Half-year to 31 December 2023</b>				
<b>Revenue</b>				
Rendering of services	3,118	1,190	24	4,332
Sales of goods	-	69	-	69
Interest and other revenue	-	-	93	93
Proceeds from sale of business	-	6,250	-	6,250
<b>Total revenue</b>	<b>3,118</b>	<b>7,509</b>	<b>117</b>	<b>10,744</b>
<b>Profit / (loss) before income tax expense and disposal</b>	<b>736</b>	<b>(29)</b>	<b>(330)</b>	<b>377</b>
Income tax expense	-	(17)	(170)	(187)
Loss on sale of business including transaction costs	-	(1,922)	-	(1,922)
<b>Profit / (loss) after income tax expense and disposal</b>	<b>736</b>	<b>(1,968)</b>	<b>(500)</b>	<b>(1,732)</b>
Depreciation and amortisation of segment assets	567	80	11	658
<b>As at 30 June 2024</b>				
Total Assets	16,205	-	13,652	29,857
Total Liabilities	(2,667)	-	(11,218)	(13,885)

	31 December 2024 \$'000	30 June 2024 \$'000
--	-------------------------------	---------------------------

Note 8: Current assets – trade and other receivables

Trade receivables	897	997
Less: Allowance for expected credit loss	(18)	(18)
	<u>879</u>	<u>979</u>
Deferred consideration for sale of pharmacy software business receivable	-	1,255
Other receivables	33	37
<b>Total trade and other receivables</b>	<b><u>912</u></b>	<b><u>2,271</u></b>

Notes to the Consolidated Financial Statements for the half-year ended  
31 December 2024

	31 December 2024 \$'000	30 June 2024 \$'000
Goodwill – at cost	2,115	2,115
Accumulated impairment	-	-
	<b>2,115</b>	<b>2,115</b>
Software product development – at cost	10,544	10,958
Research and development incentives	(1,580)	(1,294)
Accumulated amortisation	(2,570)	(2,371)
	<b>6,394</b>	<b>7,293</b>
Customer Contracts/Relationships – at cost	3,833	3,833
Accumulated amortisation	(1,187)	(1,050)
	<b>2,646</b>	<b>2,783</b>
Pharmx brand – at cost	739	739
Accumulated impairment	-	-
	<b>739</b>	<b>739</b>
<b>Total intangible assets</b>	<b>11,894</b>	<b>12,930</b>

Consolidated	Goodwill \$'000	Software product development \$'000	Brand \$'000	Customer Contracts/ Relationships \$'000	Total \$'000
<b>Balance at 1 July 2023</b>	<b>2,115</b>	<b>7,448</b>	<b>739</b>	<b>3,057</b>	<b>13,359</b>
Additions	-	1,180	-	-	1,180
Research and development incentives	-	(513)	-	-	(513)
Amortisation	-	(822)	-	(274)	(1,096)
<b>Balance at 30 June 2024</b>	<b>2,115</b>	<b>7,293</b>	<b>739</b>	<b>2,783</b>	<b>12,930</b>
Additions	-	655	-	-	655
Research and development incentives	-	(285)	-	-	(285)
Reduced settlement of Pharmxchange asset acquisition	-	(824)	-	-	(824)
Amortisation	-	(445)	-	(137)	(582)
<b>Balance at 31 December 2024</b>	<b>2,115</b>	<b>6,394</b>	<b>739</b>	<b>2,646</b>	<b>11,894</b>

## Notes to the Consolidated Financial Statements for the half-year ended 31 December 2024

### Note 9: Non-current assets – intangibles continued

On 4 December 2024 Pharmxchange Pty Ltd (Pharmxchange), a wholly owned subsidiary of the Company, executed a deed of termination of the revenue share arrangement with Alchemy to take advantage of certain provisions of the agreement which allowed Pharmxchange to prepay the remaining revenue share in accordance with a predetermined formula.

In addition to the outstanding amount payable under the minimum revenue share arrangement of \$200,000, Pharmxchange paid an additional \$75,000 as full and final settlement of the revenue share arrangement under the terms of the agreement. This resulted in a reduction in the unamortised liability under the agreement of \$824,000. As this amount related to the original maximum amount payable for the intellectual property this amount was netted against intangible assets, where the original asset was recognised.

Alchemy is a related party of both Pharmx and Pharmxchange for the purposes of Chapter 2 of the Corporations Act 2001 as they have a common director, Nick England, who did not vote on or participate in the negotiation of the settlement.

Research and development tax benefits are offset against related software development costs when they are capitalised. The research and development tax benefit in the Consolidated Statement of Profit or Loss and Other Comprehensive Income is reduced accordingly.

Goodwill was recognised on acquisition of Pharmx in the year ended 30 June 2021.

### Note 10: Issued capital, dividends and distributions

Movement in ordinary share capital	Shares	\$'000
Balance at 1 July 2024	598,506,789	93,970
Performance rights exercised	-	-
<b>Balance at 31 December 2024</b>	<b>598,506,789</b>	<b>93,970</b>

There were no dividends paid, recommended or declared during the current half-year or previous financial year or subsequent to the end of the current half-year.

### Note 11: Events after the reporting period

No matters or circumstances have arisen since 31 December 2024 that have significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

## Directors' Declaration

In the opinion of the Directors of Pharmx Technologies Limited:

- (a) The financial statements and notes, set out on pages 7 to 19 are in accordance with the Corporations Act 2001, including:
  - (i) giving a true and fair view of the Consolidated Entity's financial position as at 31 December 2024 and of its performance for the half-year ended on that date; and
  - (ii) complying with Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
- (b) There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the Board of Directors made pursuant to section 303(5) of the Corporations Act 2001.

On behalf of the Board



**Nick England**  
Chairman



**Jon Newbery**  
Director

Dated: 19 February 2025



## INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of PharmX Technologies Limited

### Report on the Half-Year Financial Report

#### Conclusion

We have reviewed the half-year financial report of PharmX Technologies Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2024, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, material accounting policy information and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- i. Giving a true and fair view of the Group's financial position as at 31 December 2024 and of its financial performance for the half-year ended on that date; and
- ii. Complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

#### Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.



#### Responsibility of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

#### Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2024 and its financial performance for the half-year ended on that date and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO Audit Pty Ltd

Vijyata Kirpalani  
Director

Sydney, 19 February 2025



pharmx

PHARMX TECHNOLOGIES  
LIMITED

ABN: 25 000 091 305

Telephone: 1300 724 579  
Email: [info@pharmx.com.au](mailto:info@pharmx.com.au)

[pharmx.com.au](http://pharmx.com.au)